Eli Lilly is spending $6.3 billion to own the orexin system.
The pharmaceutical company announced on Monday that it will acquire Centessa Pharmaceuticals, a UK-domiciled clinical-stage biotech, for $38 per share in cash plus a contingent value right worth up to $9 per share if certain regulatory milestones are met — for a total potential deal value of $47 per share. The upfront cash represents a 40.5 percent premium to Centessa's 30-day volume-weighted average share price. The deal is structured as a scheme of arrangement under English law, subject to shareholder and court approval, and is expected to close in the third quarter of 2026.
The target is not a single drug. It is a biological system.
Centessa's lead candidate is cleminorexton — formerly ORX750 — an orexin receptor 2 agonist that has demonstrated what the company calls a "best-in-class profile" in Phase 2a studies across three distinct sleep-wake conditions: narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia. The orexin system is the brain's mechanism for maintaining wakefulness. In narcolepsy type 1, the orexin-producing neurons are destroyed — a loss that leaves the sleep-wake switch permanently stuck in the off position. OX2R agonists like cleminorexton directly activate the receptor, bypassing the lost orexin neurons and restoring what the literature describes as natural sleep-wake architecture rather than pharmacological wakefulness. That is a different mechanism than stimulants, which have been the standard of care for decades.
The CVR structure is worth examining closely. The $9 per share in contingent payments breaks into three tranches: $2 upon FDA approval for narcolepsy type 2, $5 for approval in idiopathic hypersomnia, and $2 for first approval of either cleminorexton or ORX142 for any indication before January 1, 2030 PR Newswire. That structure means Lilly is paying $6.3 billion with conviction on the core indication, while hedging the broader label expansion with milestone payments that only trigger on regulatory success. It is a classic pharma risk-sharing structure for a mechanism that is genuinely novel.
Lilly is not entering sleep medicine cold. The company has been building in this space, and the Centessa acquisition adds depth to what is becoming a broader platform bet on the orexin system — the "master switch" of the sleep-wake cycle, in the language of the announcement — across a range of neurological conditions. Centessa's pipeline includes additional clinical and preclinical OX2R agonists with potential applications beyond sleep, in neurodegenerative and neuropsychiatric conditions.
The competitive dynamics are tightening. Takeda's TAK-861 had its NDA accepted by the FDA in February 2026 with Priority Review granted, building on Breakthrough Therapy designation from earlier — with GlobalData forecasting $1.26 billion in 2031 sales Takeda/BusinessWire Clinical Trials Arena. Alkermes is also advancing its alixorexton into Phase 3 in the first quarter of 2026 Clinical Trials Arena. What Centessa has that matters is depth: a portfolio rather than a single candidate, a team with specific orexin expertise, and Phase 2a data demonstrating the profile across indications. That combination is what $6.3 billion buys. Centessa itself was assembled in 2021 from a merger of 10 companies backed by $250 million from Medicxi and Index Ventures [BioPharma Dive].
There is also a human dimension worth noting. Mario Alberto Accardi, who founded Centessa's orexin program and previously ran Orexia Therapeutics before it was folded into Centessa, became CEO on January 1, 2026, succeeding Saurabh Saha. He is now steering a $6.3 billion exit less than three months into the job — a sharp turn for a pipeline he helped build.
What it means for patients is also worth saying plainly. Narcolepsy type 1 is a disabling condition with limited effective treatments. The orexin deficiency that causes it was identified in the late 1990s and the therapeutic implications have been slow to materialize. Cleminorexton, if approved, would represent a direct pharmacological restoration of the lost mechanism — not wakefulness from stimulant stimulation but wakefulness from replacing the signal that is missing. Whether the Phase 2a data supports that characterization in full is the question regulators will now work through.
The deal closes expected third quarter 2026, subject to approval. The orexin system is already active.
